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Abstract  Background. Multi-drug resistant bacteria are 
a growing concern in healthcare. Daptomycin is being used 
with increasing frequency in the treatment of 
vancomycin-resistant enterococci (VRE) and 
methicillin-resistant Staphylococcus aureus (MRSA) 
bacteremias in hemodialysis (HD) patients. Thrice-weekly 
dosing of daptomycin in this population would allow for 
coordination of dosing with common outpatient HD 
schedules. The aim of this study is to determine if 
thrice-weekly dosing of daptomycin is equivalent to dosing 
every 48 hours in patients receiving chronic intermittent 
hemodialysis. Equivalence will be assessed with regard to 
microbiological cure, clinical cure, hospital length of stay, 
and mortality. Methods. All patients with positive blood 
cultures who received at least one dose of daptomycin 
between January 1st 2009 and December 31st 2010 at 
Indiana University Health Methodist and University 
Hospitals were identified. Adult patients with end-stage 
renal disease on a stable thrice-weekly hemodialysis 
regimen, confirmed VRE or MRSA bacteremia, and at least 
three doses of inpatient daptomycin therapy were enrolled 
in the study. Results. Twelve patients met criteria for 
inclusion in this study. Nine received daptomycin every 48 
hours for the treatment of bacteremia, and three received 
daptomycin thrice-weekly after dialysis. There was no 
difference in time to clearance of blood cultures between 
the Q48H and thrice-weekly groups (2.11±2.15 days vs. 
4.33±4.16 days; p=0.241).Length of hospital stay was not 
statistically significantly different between the two groups 
(22.8 days vs. 14.9 days; p=0.065).Conclusions. 
Thrice-weekly dosing of daptomycin may be effective for 
the treatment of bacteremia in hemodialysis patients. 
Keywords  Bacteremia, Daptomycin, Hemodialysis, 
MRSA, VRE 
1. Introduction
Multi-drug resistant bacteria are a growing concern in 
healthcare. Two increasingly problematic gram-positive 
pathogens are methicillin-resistant Staphylococcus aureus 
(MRSA) and vancomycin-resistant enterococci (VRE). 
Greater than 50% of S. aureus isolates are considered 
methicillin-resistant, and vancomycin remains the first-line 
treatment for MRSA infections.[1-3] The Clinical 
Laboratory and Standards Institute (CLSI) and European 
Committee on Antimicrobial Susceptibility Testing 
(EUCAST) define strains with a minimum inhibitory 
concentration (MIC) of ≤ 2mCg/mL as susceptible to 
vancomycin, meaning there is a high likelihood of 
therapeutic success if this agent is used. However, available 
literature indicates that higher MICs (i.e. ≥ 1.5mCg/mL) are 
associated with increased risk of treatment failure in 
bacteremia.[2,3] Thus, patients with infections due to MRSA 
with elevated vancomycin MICs may be candidates for 
treatment with alternative antibiotics, such as daptomycin. 
Approximately 95% of VRE strains identified in the 
United States are Enterococcus faecium. Isolates of 
Enterococcus with MICs of > 4mCg/mL have a high 
likelihood of treatment failure and are thus considered 
resistant to vancomycin. These organisms also possess 
intrinsic resistance to many other antibiotic classes, and 
treatment options are limited to linezolid, 
quinupristin/dalfopristin, and daptomycin.[4] 
General risk factors for MRSA and VRE bacteremia 
include previous exposure to broad-spectrum antibiotics, 
prolonged hospitalization (>5 days), admission to the 
intensive care unit, and the presence of invasive devices.[5,6] 
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In addition to frequently possessing these risk factors, 
hemodialysis (HD) patients are often immunocompromised 
and repeated exposure to healthcare settings increases their 
likelihood of developing MRSA or VRE bacteremia 
requiring treatment. 
According to the package insert, the recommended dosing 
of daptomycin for the treatment of bacteremia in patients 
receiving HD is 6mg/kg IV every 48 hours.[7] In contrast, 
the Infectious Disease Society of America recommends 
administering 6mg/kg IV after each dialysis session.[8] A 
growing body of pharmacokinetic data exists to support 
post-dialysis dosing, but clinical evidence is limited. If 
effective, thrice-weekly post-dialysis dosing could provide 
significant benefits including completion of therapy in the 
outpatient setting, improved convenience for both the patient 
and the healthcare provider, and significant cost savings. 
The objective of this study was to assess clinical outcomes 
in chronic hemodialysis patients with MRSA or VRE 
bacteremia treated with thrice-weekly compared to Q48H 
daptomycin and to determine if these two dosing schedules 
may be equivalent in this population. 
2. Subjects and Methods 
2.1. Selection Criteria 
All patients who received at least one dose of daptomycin 
between January 1st 2009 and December 31st 2010 at 
Methodist and Indiana University Hospitals were identified. 
Subjects were included if they were at least 18 years old, had 
end-stage renal disease on a stable thrice-weekly HD 
regimen, had an MRSA or VRE bacteremia confirmed by at 
least one positive blood culture, received three or more doses 
of daptomycin on one of the study schedules, and had at least 
three recorded white blood cell (WBC) counts. Subjects who 
had a polymicrobial (gram-positive and gram-negative) 
bacteremia or clearly identifiable concomitant MRSA 
pneumonia were excluded from the study. Subjects were also 
excluded if they had received daptomycin within 30 days 
prior to admission or had any deviation from the study 
regimen. The study was reviewed and approved by the 
Indiana University-Purdue University Indianapolis/Clarian 
Institutional Review Board. 
2.2. Data Collection 
Data were obtained through a retrospective review of 
electronic medical records. Demographic information 
included age, gender, height, weight, and comorbidities. 
Length of hospital stay, in-hospital mortality, identity of the 
isolate (MRSA or VRE) and its susceptibility (MIC) to 
vancomycin and daptomycin were also recorded. Clinical 
indicators of infection, including daily maximum 
temperature (Tmax) and WBC count, were tracked. Date of 
first positive blood culture and first completely negative 
blood culture were used to assess microbiologic cure. 
2.3. Outcome Measures 
The primary outcome of this study was occurrence of 
microbiological cure (clearance of blood cultures) prior to 
discharge. Secondary outcomes included occurrence of 
clinical cure (Tmax < 38.3°C, WBC < 11.5 cells/mm3) prior 
to discharge, length of hospital stay, and in-hospital 
mortality. 
2.4. Statistical Analysis. 
A Kolmogorov-Smirnov test was used to determine the 
normality of distribution of the data. Fisher’s exact and 
chi-square tests were used to compare demographic 
characteristics between cohorts, and Student’s t-test was 
used to compare continuous data. A p-value of less than or 
equal to 0.05 was considered to indicate a statistically 
significant difference. 
3. Results 
Twelve patients met inclusion criteria for this study. Nine 
subjects received daptomycin every 48 hours for treatment of 
bacteremia and three received daptomycin thrice-weekly 
after dialysis. Patient demographic characteristics are shown 
in Table 1.Of the twelve subjects, nine had VRE, two had 
MRSA, and one had concomitant VRE and MRSA. The 
MICs of the isolates to vancomycin and daptomycin are 
shown in Figures 1 and 2, respectively. Of note, two MRSA 
isolates had MIC ≤ 1 mg/dL to vancomycin and thus may 
have been treated effectively with vancomycin. However, 
one isolate was identified in an individual with a documented 
vancomycin allergy, and the other was identified 
concomitantly with VRE. The maximum MIC to daptomycin 
in the identified organisms was 3 mg/dL. 
The mean dose of daptomycin received was 7.8 ± 1.4 
mg/kg (based on actual body weight) for the Q48H group, 
compared to 7.2 ± 1.2 mg/kg for the thrice-weekly group 
(p=0.517).Doses ranged from 5.8 to 10.6 mg/kg in the Q48H 
group and from 5.9 to 8.3 mg/kg in the thrice-weekly group. 
All patients achieved microbiological cure, defined as the 
clearance of blood cultures prior to hospital discharge. There 
was no difference in time from initiation of daptomycin 
therapy to clearance of blood cultures between the Q48H and 
thrice-weekly groups (2.11±2.15 days vs. 4.33±4.16 days; 
p=0.241).All study subjects demonstrated clearance of 
cultures within five days of initiating daptomycin therapy, 
with the exception of the single subject infected with both 
MRSA and VRE who was treated for 9 days before cultures 
were completely negative (Figure 3). There was no 
relationship between time to culture clearance and 
daptomycin dose. 
No patients were febrile (Tmax ≥ 38.3°C) upon initiation 
of daptomycin, and only three patients in the Q48H group 
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had a clinically significant WBC count (defined as > 11.5 
cells/mm3 at the study institutions) on initiation of 
daptomycin. Length of hospital stay was not significantly 
different between the two groups, however a trend toward 
shorter length of stay was noted in the thrice-weekly group 
(22.8 days vs. 14.9 days; p=0.065). 
Table 1.  Subject Demographic Characteristics 
Characteristic Value 
 Thrice-Weekly Q48H 
Age (years)* 55 (32 – 57) 58 (27 – 64) 
Female 0 (0) 5 (55.6) 
Male 3 (100) 4 (44.4) 
Actual Body Weight (kg)* 81 (60 – 135) 64 (55 – 88) 
Dose (mg/kg ABW)* 7.4 (5.9 – 8.3) 7.9 (5.8 – 10.6) 
Length of Stay* 14.9 (7.8 – 17.9) 22.8 (5.9 – 75) 
In-hospital mortality# 0 (0) 0 (0) 
*Median (Range), #Number (%) 
 
Figure 1.  Minimum Inhibitory Concentrations (MICs) of Study Isolates to Vancomycin. 
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Figure 2.  Minimum Inhibitory Concentrations (MICs) of Study Isolates to Daptomycin. 
 
Figure 3.  Time to Clearance of Blood Cultures. 
4. Discussion 
Daptomycin is being used with increasing frequency in the 
treatment of MRSA and VRE bacteremia in HD patients. 
Thrice-weekly dosing would provide significant cost savings 
to the healthcare system. Perhaps more importantly, 
thrice-weekly dosing of daptomycin would be more 
convenient for both patients and healthcare providers when 
treatment can be completed on an outpatient basis. The 
combination of these benefits has the potential to drastically 
increase adherence to prescribed antibiotic regimens. 
However, these potential benefits are of no value if 
thrice-weekly dosing of daptomycin proves ineffective. 
Further studies to confirm that thrice-weekly dosing is 
non-inferior to Q48H dosing for the treatment of bacteremia 
are thus justified. 
Salama and colleagues published a pharmacokinetic study 
in which six non-bacteremic HD patients were given a single 
6mg/kg IV dose of daptomycin following an HD session.[9] 
Serial blood samples were collected for 44 hours after the 
dose and throughout the subsequent session. This data was 
then used to model trough serum concentrations at 44 and 68 
hours after 6mg/kg, 8mg/kg, and 10mg/kg post-HD doses. 
Based on their results, the authors predicted that HD patients 
would maintain daptomycin concentrations sufficiently 
above the MIC of S. aureus (≤ 1mCg/mL) and E. faecium (≤ 
4mCg/mL) at 68 hours after a 6, 8, or 10 mg/kg dose. This 
suggests that HD patients should be able to receive 
thrice-weekly post-dialysis doses of daptomycin rather than 
Q48H, allowing for coordination of dosing with common 
outpatient HD schedules (e.g., every 
Monday/Wednesday/Friday). 
Patel and colleagues used pharmacokinetic modeling and 
Monte Carlo simulations in effort to characterize daptomycin 
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pharmacokinetics in HD patients and identify an ideal dosing 
regimen for HD patients receiving daptomycin therapy.[10] 
Blood samples were collected from twelve non-bacteremic 
HD patients over three consecutive days during the patient’s 
regular dialysis routine. A single dose of daptomycin 6mg/kg 
IV was administered to each patient on study day 1 after 
hemodialysis. The mathematic models employed in this 
study demonstrated that administering daptomycin during or 
immediately following HD results in pharmacokinetic values 
similar to those seen in studies of non-dialysis patients. 
Based on their results, the authors suggest that it may be 
appropriate to administer a 50% larger daptomycin dose 
prior to a two day dialysis holiday (i.e. with Friday dialysis in 
patients receiving HD every Monday/Wednesday/Friday or 
with Saturday dialysis in patients receiving HD every 
Tuesday/Thursday/Saturday). 
In effort to develop a single, 
pharmacokinetically-optimized daptomycin dosing regimen 
for the dialysis population, data from Salama and Patel was 
pooled along with data from a multiple-dose kinetic study 
conducted by Benziger et al.[11,12] Results of the combined 
analysis support the recommendation that administration of 
standard daptomycin doses during or post-HD on dialysis 
days, with a 50% dose increase prior to the 72-hour 
interdialytic period will achieve daptomycin concentrations 
that most closely resemble exposure to Q24H dosing in 
non-dialysis patients. 
While results of these pharmacokinetic studies suggest a 
high likelihood of success when daptomycin is administered 
thrice-weekly with dialysis, clinical evidence is still lacking. 
The current study found no statistically significant difference 
in microbiological cure between patients who received 
daptomycin thrice-weekly after dialysis and those who 
received the antibiotic on a Q48H regimen. It should be 
noted that the average daptomycin doses used in these 
patients were higher than currently recommended (7.7 mg/kg 
vs. 6mg/kg). 
In designing this study, the intent was to assess the time to 
clinical cure using common indicators of infection: 
temperature and WBC counts. Despite having documented 
bacteremia, none of the subjects observed were febrile upon 
initiation of daptomycin. One possible explanation for this is 
that hemodialysis alters body temperature regulation, and 
HD patients may have an altered fever response in the setting 
of infection.[13] Similarly, only 3 patients in the Q48H 
group had elevated WBC counts above 11.5 cells/mm3 at the 
initiation of daptomycin, possibly due to an overall 
immunocompromised state and inability to mount an 
appropriate response to infection. This interesting 
observation suggests that we may not be able to rely on 
generally accepted clinical indicators to identify infection or 
to assess clinical status and cure. 
This study has several limitations which must be noted. 
First of all, the practice of administering daptomycin 
thrice-weekly after dialysis was a somewhat novel concept at 
the beginning of the study period. This is believed to be a 
large contributing factor to the small study population 
identified. The retrospective nature of the study inherently 
eliminates the opportunity to establish a study protocol. Thus, 
blood cultures were checked and re-checked at the discretion 
of the provider, and there were no guidelines for 
standardized dosing of daptomycin. Finally, as discussed 
previously, the effects of hemodialysis and overall 
immunocompromised status of patients in this study 
population make it challenging to assess the impact of 
treatment on indicators of clinical cure. 
The treatment of multi-drug resistant bacteremia in the 
end-stage renal disease population is often multifactorial and 
complicated by comorbid conditions and unconventional 
clinical responses to therapy. While the results of this study 
cannot establish noninferiority of thrice-weekly daptomycin 
compared to Q48H dosing, they do provide evidence to 
support further research. 
5. Conclusion 
Other studies have aimed to better characterize the 
pharmacokinetics of daptomycin in hemodialysis patients 
and determine the most appropriate dosing regimen in this 
population. To the best of our knowledge, this is the first 
attempt to compare clinical outcomes in patients treated with 
thrice-weekly, post-dialysis daptomycin to those of patients 
treated with every 48 hour dosing. Although our study 
population was small, the results suggest that the use of more 
convenient and less costly thrice-weekly dosing may be an 
appropriate approach for the treatment of bacteremia in 
patients on hemodialysis. 
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